KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Shares Outstanding (Diluted Average) (2020 - 2025)

Aurinia Pharmaceuticals' Shares Outstanding (Diluted Average) history spans 6 years, with the latest figure at $138.7 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) fell 5.13% year-over-year to $138.7 million; the TTM value through Dec 2025 reached $138.7 million, down 5.13%, while the annual FY2025 figure was $138.7 million, 5.13% down from the prior year.
  • Shares Outstanding (Diluted Average) reached $138.7 million in Q4 2025 per AUPH's latest filing, roughly flat from $139.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $146.2 million in Q4 2024 to a low of $127.4 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $139.7 million, with a median of $141.9 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding (Diluted Average): increased 13.72% in 2021, then fell 5.13% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $129.4 million in 2021, then rose by 9.7% to $141.9 million in 2022, then grew by 0.93% to $143.2 million in 2023, then grew by 2.07% to $146.2 million in 2024, then dropped by 5.13% to $138.7 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Shares Outstanding (Diluted Average) are $138.7 million (Q4 2025), $139.0 million (Q3 2025), and $140.2 million (Q2 2025).